Frost & Sullivan Recognizes BeneChill's Groundbreaking Intranasal Cooling System for Therapeutic Hypothermia

Frost & Sullivan Recognizes BeneChill'sFrost & Sullivan Recognizes BeneChill's Groundbreaking Intranasal Cooling System for Therapeutic Hypothermia PR Newswire MOUNTAIN VIEW, California, Jan. 20, 2014 -- BeneChill's RhinoChill helps achieve effective, time critical, and safe brain cooling in both pre-clinical as well as clinical settings Based on its recent analysis of the therapeutic hypothermia market for cardiology, Frost & Sullivan recognizes BeneChill, Inc. with the 2014 Frost & Sullivan Award for Technology Innovation Leadership. BeneChill's RhinoChill intranasal cooling system is a nasopharyngeal device that can induce therapeutic hypothermia during active resuscitation after a cardiac arrest and continue maintaining the temperature while the patient is in an ambulance. The system is unique—it is noninvasive, time critical, and can be used by nonmedical personnel in the field to prevent brain damage associated with cardiac arrest. RhinoChill is a portable and battery-operated device composed of a control unit, coolant bottle, and a transnasal cooling catheter, which makes the device ideal for use outside the hospital setting. The technology enables brain cooling close to the time of cerebral ischemic events, even in the absence of blood circulation.